Position of the Transparency Council – Opdivo (nivolumab)
At its meeting on 21 October 2024, the Transparency Council adopted position No. 110/2024 on the evaluation of the drug Opdivo (nivolumab) within the framework of the drug program B.59. “Treatment of patients with melanoma of the skin or mucous membranes (ICD-10: C43)”